SAPROCAN: Saracatinib and docetaxel in met, cast-ref prostate cancer
Research type
Research Study
Full title
SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group
IRAS ID
58590
Contact name
Robert Jones
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Eudract number
2010-021447-41
ISRCTN Number
ISRCTN22566729
Research summary
In this study (SAPROCAN) we are investigating whether we can improve the benefits of anti-cancer chemotherapy by adding a new drug called saracatinib (also known as AZD0530). Although there are good scientific reasons from laboratory studies why saracatinib should work on prostate cancer cells, it has not been tested in a large number of men with prostate cancer. Some early clinical studies have also shown that saracatinib has an effect on bones which may be beneficial for men with prostate cancer, but we don??t yet know whether the drug will be effective in treating prostate cancer. For this reason we propose to treat some men with standard chemotherapy drugs alone and some men with the new drug during chemotherapy and continued after chemotherapy has finished. The purpose of this study is to find out whether saracatinib makes chemotherapy more effective, without producing side effects that interfere too much with day to day life. In order to study this we need to conduct a randomised controlled trial.
REC name
West of Scotland REC 1
REC reference
11/AL/0081
Date of REC Opinion
7 Apr 2011
REC opinion
Further Information Favourable Opinion